Bicycle Therapeutics Plc (BCYC)

3.46 -0.14 (-3.89%) USD  |  NASDAQ  |  Oct 16, 16:00
3.455 0.00 (0.00%) After-Hours: 20:00
More

Bicycle Therapeutics Cash from Investing (Quarterly) : -0.266M for June 30, 2026

Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -0.266M
March 31, 2026 -0.7118M
December 31, 2025 -0.5731M
September 30, 2025 -0.6709M
June 30, 2025 -0.5052M
March 31, 2025 -0.6063M
December 31, 2024 -0.3646M
September 30, 2024 -0.4388M
June 30, 2024 -0.4201M
March 31, 2024 -0.012M
December 31, 2023 -0.0496M
September 30, 2023 -0.4997M
June 30, 2023 -0.273M
March 31, 2023 -2.118M
December 31, 2022 -1.617M
September 30, 2022 -2.892M
June 30, 2022 -9.738M
Date Value
March 31, 2022 -4.729M
December 31, 2021 -1.064M
September 30, 2021 -0.1706M
June 30, 2021 -0.1694M
March 31, 2021 -0.6252M
December 31, 2020 -0.4904M
September 30, 2020 -0.0969M
June 30, 2020 -0.3019M
March 31, 2020 -0.3202M
December 31, 2019 -0.3958M
September 30, 2019 -0.282M
June 30, 2019 -0.4612M
March 31, 2019 -0.4224M
December 31, 2018 -0.4077M
September 30, 2018 -0.1273M
June 30, 2018 -0.3827M
March 31, 2018 -0.2658M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Autolus Therapeutics Plc 68.03M
Cellectis SA 18.75M
Akari Therapeutics Plc 0.00
DBV Technologies SA -0.5998M
Biodexa Pharmaceuticals Plc --

Cash from Investing (Quarterly) Related Metrics

Cash from Operations (Quarterly) -49.69M
Cash from Financing (Quarterly) -0.0501M
Free Cash Flow -207.47M
Free Cash Flow Per Share (Quarterly) -0.7157
Free Cash Flow to Equity (Quarterly) -49.23M
Free Cash Flow to Firm (Quarterly) -49.92M
Free Cash Flow Yield -86.23%